TerminatedNot Applicable

The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study

Stopped: Study follow-up duration impacted by COVID-19pandemic and Sponsor terminated for business reasons

United States764 participantsStarted 2017-03-30

Plain-language summary

To examine the current disease progression of PDP, the clinical, economic, and humanistic impact of anti-psychotic therapy in the management of the condition in real-world settings, and the burden of the condition on patients and their caregivers

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adult males and females ≥ 18 with PDP
✓. Ability to understand and read English
✓. Patient is willing and able to sign an Informed Consent Form (ICF), or have a Legally Authorized Representative willing and able to consent on the patient's behalf
✓. Possess the symptoms commonly associated with PDP, e.g., hallucinations and delusions that cannot be reasonably attributed to other causes

Exclusion criteria

✕. Patient is unwilling to participate in the non-interventional study
✕. Patient is currently participating in or is planning to participate in an investigational clinical trial

What they're measuring

The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice)

Timeframe: Approximately 36 months

Trial details

NCT IDNCT03152292

SponsorACADIA Pharmaceuticals Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2021-03-08

View on ClinicalTrials.gov More Parkinson Disease Psychosis trials